AUG 18, 2026 · PHASE 1 TRIAL
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
ClinicalTrials.gov
Phase 1 trial in early-stage development testing immunogenicity of a novel MUC1 vaccine in DCIS; no efficacy or clinical outcomes reported, and results are not yet posted in this registry record.
Reported
Estimated enrollment50
PhasePHASE 1
Primary outcome measureImmunogenicity (of MUC1 vaccine) at Week 12